Antisense Therapeutics Limited (ASX:ANP) has announced that it intends to conduct a double-blind, placebo-controlled six-month dosing trial of ATL1102 followed by a six-month open-label phase 2b trial in non-ambulant boys with Duchenne’s Muscular Dystrophy. …
Antisense Therapeutics announces revised clinical development plan for ATL1102
September 8, 2022 Australian Biotech
Latest Video
New Stories
-
Australian researcher awarded Gilead Sciences global grant to explore novel approach in breast cancer
July 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 July
July 17, 2025 - - Podcast -
Another day, another confusing response to the threat of US tariffs
July 17, 2025 - - Latest News -
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News